Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,935.00
Bid: 1,921.00
Ask: 1,923.00
Change: 11.00 (0.57%)
Spread: 2.00 (0.104%)
Open: 1,902.00
High: 1,935.00
Low: 1,902.00
Prev. Close: 1,924.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK MARKET TALK ROUNDUP: BROKERS COMMENTS

Tue, 06th Jul 2010 07:53

Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, markets.eu@dowjones.com Contact us in London. +44-20-7842-9464 Markettalk.eu@dowjones.com 0653 GMT [Dow Jones] Royal Bank of Scotland initiates coverage on Hikma Pharmaceuticals (HIK.LN), with a hold rating and 750p target price. "Our optimistic forecasts reflect Hikma's strong position in MENA [Middle East and North Africa] and its strategy of globalizing the platform, which should allow it to compete effectively in the US and Europe," it says. However, sees execution risk associated with the successful implementation of the global platform strategy, and with structuring value-accretive deals in an increasingly competitive M&A environment in the MENA region. "We believe the current valuation fairly reflects our (and consensus) sales and earnings growth estimates. We await more clarity on execution risks before re-considering our stance," it adds. Shares closed at 688p. (ishaq.siddiqi@dowjones.com) 0653 GMT [Dow Jones] Punch Taverns's (PUB.LN) trading update is in line with expectations, says KBC Peel Hunt. However, in view of the challenging trading outlook for FY '11, the brokerage downgrades its FY '11E pretax profit forecast by 7% to GBP123M. Says this assumes no LFL growth or margin improvement. Notes net debt has been reduced by GBP0.2B since the beginning of the year to GBP3.2B. Keeps the stock at hold and puts 90p price target under review. Shares closed Monday at 65p. (michele.maatouk@dowjones.com) 0652 GMT [Dow Jones] Goldman Sachs downgrades Majestic Wine (MJW.LN) to neutral from buy following the stock's recent outperformance. Notes that since being added to the buy list on April 22, the stock is up 9.2% vs the FTSE World Europe. Still, "we continue to view Majestic's superior sales performance, solid margins and strong returns as worthy of a multiple more in line with the EU Retail sector's historical EV/Ebitda median of 8.9x than with its own historical median of 7.7x." Keeps price target at 370p. Shares closed Monday at 308p. (michele.maatouk@dowjones.com) 0649 GMT [Dow Jones] Royal Bank of Scotland upgrades BP (BP.LN) to buy from hold, but cuts its price target at 455p from 595p. Says a decline in BP's value of $60B relative to closest peers since the Macondo oil spill blowout has created a favorable risk/reward balance. Expects the first relief well to intersect the Macondo bore by mid-July, which will be a turning point for BP's share price. "Stopping the flow of oil will cap the physical volume of the spill, reduce the daily costs being incurred, cool the political temperature and, if BP's share price remains excessively depressed, it could trigger credible merger speculation," adds RBS. Shares closed at 333p. (ishaq.siddiqi@dowjones.com) 0634 GMT [Dow Jones] Tullow Oil (TLW.LN) appears to be on track to close its Uganda asset deal with Heritage Oil (HOIL.LN), Total (TOT) and Cnooc (CEO), says Panmure Gordon analyst Peter Hitchens. "It appears Tullow has everything all sorted out apart from getting it all signed," he said, adding that full closure of the deal may take a few more weeks. Tullow will probably have little news to drive shares over the summer, but in September will drill new wells that are potentially very exciting, he adds. Gives 1500p target, buy rating. Shares closed down 0.5% Monday at 1041p. (james.herron@dowjones.com) 0628 GMT [Dow Jones] PartyGaming's (PRTY.LN) trading update for the second quarter is better than expected, Numis Securities analyst Wyn Ellis says. Adds the group's statement that it is committed to play an active role in sector consolidation will go down well with investors. Has a buy rating and 400p target price. Shares closed Monday at 221p. (simon.zekaria@dowjones.com) 0627 GMT [Dow Jones] UBS upgrades Debenhams (DEB.LN) to buy from neutral, but nudges down its price target to 75p from 77p. Says the company looks cheap on all metrics following a 20% underperformance of the UK retail sector in the last three months. Expects the management to increase focus on delivering market share gains and positive like-for-like sales growth. "The upcoming refinancing and expected reinstatement of a dividend in FY '11 should convince investors of the longer-term investment case." Shares closed Monday at 57p. (michele.maatouk@dowjones.com) 0626 GMT [Dow Jones] Persimmon (PSN.LN) reports very positive numbers ahead of the first half so shares are likely to rise after the statement, says Liberum Capital analyst. Says the company already sold GBP1.5 billion worth of homes for the year, which is really good news and that margins are also ahead of expectations. Adds that borrowings are also lower than expected. Has hold rating. Shares closed Monday at 348p. (anita.likus@dowjones.com) 0625 GMT [Dow Jones] UBS upgrades GKN (GKN.LN) to buy from neutral. Says the recent decline in its share price offers a good opportunity to buy the stock again. "Although our investment case and profit forecasts are unchanged, we believe the lower valuation now offers an attractive risk-reward profile for investors," it says. Says GKN is a well-run business with leading technologies, strong market positions and several opportunities. "In addition, we see some further upside risk to profits. Our only major concern remains a low cash conversion, largely as a result of pension payments," adds UBS. Maintains 140p target price. Shares closed at 112p. (ishaq.siddiqi@dowjones.com) 0623 GMT [Dow Jones] Investec Securities upgrades AB Foods (ABF.LN) to buy from hold and raises target to 1080p from 1060p as it takes a more positive view of Primark's valuation ahead of the company's 3Q results on July 8. Increasingly sees Primark as a winning proposition and thinks profit growth at a rate of 12% to 14% per annum is sustainable on a five-year view. Says this merits a premium rating. Thinks the market's valuation on Primark of 7-8x Ebitda/15-16x PER is too low, and reckons 8-9x ebitda is more appropriate. Shares closed Monday at 947p. (michele.maatouk@dowjones.com) Contact us in London. +44-20-7842-9288 Markettalk.eu@dowjones.com (END) Dow Jones Newswires July 06, 2010 02:53 ET (06:53 GMT)
More News
1 Mar 2023 09:52

LONDON BROKER RATINGS: Canaccord says sell Future; Investec likes RWS

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
27 Feb 2023 09:38

Berenberg raises target price on Hikma Pharmaceuticals

(Sharecast News) - Analysts at Berenberg raised their target price on drugmaker Hikma Pharmaceuticals from 1,440.0p to 1,740.0p on Monday on the back of the group's recent trading update.

Read more
27 Feb 2023 09:26

LONDON BROKER RATINGS: Citi cuts Quilter to 'sell'; Goldman likes GSK

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
24 Feb 2023 09:37

LONDON BROKER RATINGS: SocGen cuts Burberry; BofA cuts WH Smith

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
23 Feb 2023 09:54

Hikma Pharmaceuticals profit halves in 2022 on Generics impairment

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reported a dip in annual revenue for 2022, as profit tumbled due to high inflation and adjustments regarding expectations for its Generics business.

Read more
23 Feb 2023 09:02

LONDON MARKET OPEN: Mixed open in London; Rolls-Royce up, Mondi down

(Alliance News) - Stock prices in London opened mixed on Thursday, with large-cap indices underperforming amid mixed corporate earnings.

Read more
23 Feb 2023 07:59

Competition in generics sees Hikma Pharmaceuticals's profits decline by a tenth

(Sharecast News) - Hikma Pharmaceuticals posted lower full-year profits as stiff competition in generics saw its top line growth flatten out.

Read more
23 Feb 2023 07:56

LONDON BRIEFING: WPP profit jumps in 2022; guides for further growth

(Alliance News) - Stocks in London were called to open slightly higher on Thursday, as investors were unfazed by a fairly uneventful set of policy meeting minutes from the US central bank.

Read more
22 Feb 2023 21:50

Hikma accuses Amarin of suppressing generic versions of heart pill

Hikma claims Amarin used exclusive agreements with suppliers to frustrate generic rivals

*

Read more
16 Feb 2023 15:49

UK earnings, trading statements calendar - next 7 days

Friday 17 February 
Allianz Technology Trust PLCFull Year Results
Kingspan Group PLCFull Year Results
NatWest Group PLCFull Year Results
Pod Point Group Holdings PLCFull Year Results
Segro PLCFull Year Results
Monday 20 February 
Bank of Cyprus Holdings PLCFull Year Results
Georgia Capital PLCFull Year Results
Goldplat PLCFull Year Results (TBC)
LungLife AI IncFull Year Results
Tristel PLCHalf Year Results
Wilmington PLCHalf Year Results
Tuesday 21 February 
Antofagasta PLCFull Year Results
BHP Group LtdHalf Year Results
Blancco Technology Group PLCHalf Year Results
Finsbury Food Group PLCHalf Year Results
HSBC Holdings PLCFull Year Results
InterContinental Hotels Group PLCFull Year Results
Safestore Holdings PLCTrading Statement
Smith & Nephew PLCFull Year Results
Springfield Properties PLCHalf Year Results
Sylvania Platinum LtdHalf Year Results
Trifast PLCTrading Statement
Wednesday 22 February 
Avingtrans PLCHalf Year Results
City of London Investment Group PLCHalf Year Results
Conduit Holdings LtdFull Year Results
Liberty Global PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
Primary Health Properties PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
Rio Tinto PLCFull Year Results
Synectics PLCFull Year Results
TBC Bank Group PLCFull Year Results
Transense Technologies PLCHalf Year Results
Thursday 23 February 
Anglo American PLCFull Year Results
Arbuthnot Banking Group PLCTrading Statement
BAE Systems PLCFull Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Drax Group PLCFull Year Results
Driver Group PLCFull Year Results
Genus PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Made Tech Group PLCHalf Year Results
Mondi PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Pantheon International PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
Serco Group PLCFull Year Results
Spectris PLCFull Year Results
Versarien PLCFull Year Results
WPP PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
25 Jan 2023 09:33

LONDON BROKER RATINGS: Goldman likes UK banks; HSBC cuts Dr Martens

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
18 Jan 2023 15:07

Director dealings: Hikma Pharmaceuticals director snaps up shares

(Sharecast News) - Hikma Pharmaceuticals revealed on Wednesday that non-executive director Deneen Vojta had acquired 1,000 ordinary shares in the FTSE 250-listed drugmaker.

Read more
12 Jan 2023 17:55

Arecor transfers AT307 drug to Hikma for development, regains AT282

(Alliance News) - Arecor Therapeutics PLC on Thursday said it transferred development activities for the ready-to-use injectable medicine AT307 to Hikma Pharmaceuticals PLC, and regained rights on AT282 after a product portfolio review.

Read more
3 Jan 2023 17:31

FTSE 100 ends first trading day of 2023 on upbeat note

FTSE 100 up 1.4%, FTSE 250 adds 1.5%

*

Read more
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.